UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Nuclear export of proteins and drug resistance in cancer

Biochemical pharmacology, 2012-04, Vol.83 (8), p.1021-1032

2012

Volltextzugriff (PDF)

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Clinical cancer research, 2020-01, Vol.26 (1), p.54-60

2020

Volltextzugriff (PDF)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Journal of hematology and oncology, 2016-08, Vol.9 (1), p.73-11, Article 73

2016

Volltextzugriff (PDF)

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (23), p.5344-5354

2020

Volltextzugriff (PDF)

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (17), p.6899-6905

2009

Volltextzugriff (PDF)

Abstract 289: Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.289-289

2016

Volltextzugriff (PDF)

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Clinical cancer research, 2009-04, Vol.15 (7), p.2479-2487

2009

Volltextzugriff (PDF)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Journal of Cancer, 2013-01, Vol.4 (8), p.614-625

2013

Volltextzugriff (PDF)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Oncotarget, 2016-11, Vol.7 (48), p.78896-78909

2016

Volltextzugriff (PDF)

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Clinical cancer research, 2011-12, Vol.17 (24), p.7743-7753

2011

Volltextzugriff (PDF)

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

Sarcoma, 2013, Vol.2013, p.365723-12

2013

Volltextzugriff (PDF)

Abstract 1228: Novel small molecule inhibitors that target the exportin binding pocket of TOP2A for the treatment of multiple myeloma

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1228-1228

2021

Volltextzugriff (PDF)

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Seminars in cancer biology, 2014-08, Vol.27, p.62-73

2014

Volltextzugriff (PDF)

Abstract 285: Ixazomib combined with the nuclear export inhibitors selinexor or eltanexor for the treatment of multiple myeloma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.285-285

2019

Volltextzugriff (PDF)

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

Cancer research (Chicago, Ill.), 2020-10, Vol.80 (23), p.5344-5354

2020

Volltextzugriff (PDF)

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Blood, 2017-12, Vol.130, p.3095-3095

2017

Volltextzugriff (PDF)

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.4032-4032

2012

Volltextzugriff (PDF)

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.5662-5662

2016

Volltextzugriff (PDF)

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.3299-3299

2016

Volltextzugriff (PDF)

Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8013-8013

2016

Volltextzugriff (PDF)

Abstract 1771: KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1771-1771

2012

Volltextzugriff (PDF)

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.1818-1818

2015

Volltextzugriff (PDF)

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.3048-3048

2015

Volltextzugriff (PDF)

Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4434-4434

2015

Volltextzugriff (PDF)

Abstract 2072: SNDX-275 synergistically inhibits the growth of sarcoma cells when combined with AKT inhibitors, platinum drugs and Topo II poisons

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2072-2072

2013

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(76)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(26)
Humans
(23)
Female
(14)
Male
(12)
Biological And Medical Sciences
(11)
Animals
(9)
Middle Aged
(9)
Oncology
(9)
Physical Sciences
(9)
Aged
(8)
Medical Sciences
(8)
Adult
(6)
Exportin 1 Protein
(6)
Karyopherins - Antagonists & Inhibitors
(6)
Multidisciplinary Sciences
(6)
Receptors, Cytoplasmic And Nuclear - Antagonists & Inhibitors
(6)
Science & Technology - Other Topics
(6)
Social Sciences
(6)
Antineoplastic Agents
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(14)
Blood
(10)
Clinical Cancer Research
(5)
European Journal Of Pharmacology
(3)
Plos One
(3)
Bone
(2)
Jci Insight
(2)
Journal Of Bone And Mineral Research
(2)
Wasafiri
(2)
American Journal Of Pharmaceutical Education
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nuclear export of proteins and drug resistance in cancer

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Abstract 289: Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

Abstract 1228: Novel small molecule inhibitors that target the exportin binding pocket of TOP2A for the treatment of multiple myeloma

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Abstract 285: Ixazomib combined with the nuclear export inhibitors selinexor or eltanexor for the treatment of multiple myeloma

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM)

Abstract 1771: KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma

Abstract 2072: SNDX-275 synergistically inhibits the growth of sarcoma cells when combined with AKT inhibitors, platinum drugs and Topo II poisons

Suchergebnisse filtern